Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026

ConferenceCLDN18.2 AntibodyNeutral

AI Analysis

Summary

Tsingke presented its AI-driven CLDN18.2 antibody discovery program at the Antibody Industrial Symposium 2026 in Montpellier, France. The announcement is a routine conference participation with limited material impact.

Importance:2/10

Sentiment:

0.20

AI-driven discoveryantibody developmentCLDN18.2conference presentation

Related Companies

$INBP

Read the original article

Published by PR Newswire Clinical Trials on July 8, 2026 2:17 PM

Read Original